EUVIMEDEUVIMED entdecken
Crossref

Empagliflozin Restores the Colonic Mucous Barrier by an AMPK / SOX4 ‐Dependent Pathway in Glycogen Storage Disease Type Ib

Ni Ma, Yongmei Zeng, Jing Yang, Ying Wang, Haotian Wu, Zhiling Li, Xiaoyan Zhang, Hanshi Zeng, Yuxin Zhang, Min Yang, Jiaoli Lan iD

The FASEB Journal · 31.05.2026 · 40 (10)

DOI: 10.1096/fj.202505003r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 14.05.2026. Verfasst von Ni Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Chin…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Intestinal Mucosa, AMP-Activated Protein Kinases. Die Arbeit nennt 34 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycogen storage disease type Ib (GSD‐Ib) is commonly associated with refractory inflammatory bowel disease (GSD‐IBD). Although the SGLT2 inhibitor empagliflozin has demonstrated remarkable clinical efficacy, its direct effects on the intestinal epithelium remain poorly understood. This study aimed to determine whether empagliflozin directly restores the impaired colonic mucus barrier and to identify the underlying molecular pathway. In terms of efficacy, we integrated clinical evaluations of GSD‐IBD patients with a novel murine model of epithelial injury induced by a defined bacterial consortium (EVS: Enterococcus, Veillonella, Streptococcus ) and dextran sulfate sodium (DSS). In vitro, we employed Caco‐2 cells and intestinal organoids, combined with pharmacological inhibition of AMPK and siRNA‐mediated gene knockdown to elucidate the underlying molecular mechanisms. Clinical data indicated that empagliflozin promoted ulcer healing and enhanced mucin production in patients. In the EVS + DSS mouse model, empagliflozin treatment reduced disease severity and attenuated goblet cell depletion. We demonstrated that empagliflozin upregulates the transcription factor SOX4 in intestinal epithelial cells both in vivo and in vitro, an effect dependent on AMPK activation. Notably, siRNA knockdown of SOX4 abolished empagliflozin‐induced MUC2 upregulation. Furthermore, pharmacological inhibition of AMPK suppressed the induction of MUC2, which could be rescued by SOX4 overexpression. Our findings uncover a novel, epithelium‐intrinsic mechanism of action for empagliflozin: the activation of the AMPK/SOX4/MUC2 signaling axis to restore the colonic mucus barrier. These results provide a mechanistic foundation for the repurposing of SGLT2 inhibitors in conditions characterized by epithelial barrier dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesIntestinal MucosaAMP-Activated Protein KinasesColonAnimalsHumansMiceCaco-2 CellsMaleIntestinal Barrier FunctionSignal TransductionMice, Inbred C57BLFemaleDisease Models, Animal

Stichwörter der Autor:innen

AMPK signaling pathwaySOX4empagliflozinglycogen storage disease type Ibmucous barrier

Substanzen

Benzhydryl CompoundsGlucosidesempagliflozinAMP-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Pediatrics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
  • Shenzhen Maternity and Child Healthcare Hospital, Women and Children's Medical Center, Southern Medical University, Shenzhen, China.
  • Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.

ORCID-Profile: Jiaoli Lan

Förderung

  • the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Ma, N., Zeng, Y., Yang, J., Wang, Y., Wu, H., Li, Z., Zhang, X., Zeng, H., Zhang, Y., Yang, M., & Lan, J. (2026). Empagliflozin Restores the Colonic Mucous Barrier by an AMPK / SOX4 ‐Dependent Pathway in Glycogen Storage Disease Type Ib. The FASEB Journal, 40(10). https://doi.org/10.1096/fj.202505003r

Vancouver

Ma N, Zeng Y, Yang J, Wang Y, Wu H, Li Z, et al. Empagliflozin Restores the Colonic Mucous Barrier by an AMPK / SOX4 ‐Dependent Pathway in Glycogen Storage Disease Type Ib. The FASEB Journal. 2026;40(10). doi:10.1096/fj.202505003r

BibTeX
@article{Ma2026,
  author = {Ma, Ni and Zeng, Yongmei and Yang, Jing and Wang, Ying and Wu, Haotian and Li, Zhiling and Zhang, Xiaoyan and Zeng, Hanshi and Zhang, Yuxin and Yang, Min and Lan, Jiaoli},
  title = {Empagliflozin Restores the Colonic Mucous Barrier by an AMPK / SOX4 ‐Dependent Pathway in Glycogen Storage Disease Type Ib},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {10},
  doi = {10.1096/fj.202505003r}
}
Kostenlos starten →